Recurrent High Grade Glioma Treated by LITT

Inclusion criteria

• Aged 18 years old or above;
• Patients with previous pathological diagnosis of 2021 World Health Organization Classification of Central Nervous System Tumors (WHO CNS5) grade 3 or 4 glioma and received standard treatment;
• Meet any of the following:

• Meets the disease progression criteria in the Response Evaluation of Neuro-Oncology (RANO 2.0) criteria;
• At least one image other than T1 contrast indicates progression;
• Pathology shows progression or recurrence;
• Other progress determined by the Clinical Events Committee (CEC);
• All tumor lesions are located supratentorial and the maximum cross-sectional short-axis length in the T1 contrast is ≤30 mm;
• Karnofsky score (KPS) ≥ 60 and the patient can tolerate the intervention;
• The subjects or their agent can understand the purpose of the trial, show sufficient compliance with the trial protocol, and sign the informed consent form.

Exclusion criteria

• Patients may benefit from other treatments or may not benefit from this trial;
• No more than three months since the patient underwent craniotomy;
• MRI contrast cannot be performed;
• Severe coagulation disorder;
• Women who are pregnant, lactating, or planning to become pregnant within 6 months;
• Participated in any other clinical trials of drugs or medical devices within 3 months;
• Combined diseases that may interfere with treatment or prognosis assessment;
• Refuse or unlikely to complete follow-up assessment;
• Other circumstances in which the researcher deems it inappropriate to participate in this clinical trial.